OBJECTIVE: A minor allele variant (rs3798220) of apolipoprotein(a) has been reported to be associated with elevated plasma lipoprotein(a) [Lp(a)] and increased cardiovascular risk. We investigated whether this allele was associated with elevated Lp(a) and cardiovascular risk in the Women's Health Study, a randomized trial of low-dose aspirin, and whether aspirin reduced cardiovascular risk in minor allele carriers. METHODS AND RESULTS: Genotypes of rs3798220 were determined for 25,131 initially healthy Caucasian participants. Median Lp(a) levels at baseline were 10.0, 79.5, and 153.9mg/dL for major allele homozygotes, heterozygotes, and minor allele homozygotes, respectively (P<0.0001). During the 9.9 years of follow-up, minor allele carriers (3.7%) in the placebo group had twofold higher risk of major cardiovascular events than non-carriers (age-adjusted hazard ratio (HR)=2.21, 95% CI: 1.39-3.52). Among carriers, risk was reduced more than twofold by aspirin: for aspirin compared with placebo the age-adjusted HR was 0.44 (95% CI: 0.20-0.94); risk was not significantly reduced among non-carriers (age-adjusted HR=0.91, 95% CI: 0.77-1.08). This interaction between carrier status and aspirin allocation was significant (P=0.048). CONCLUSIONS: In the Women's Health Study, carriers of an apolipoprotein(a) variant had elevated Lp(a), doubled cardiovascular risk, and appeared to benefit more from aspirin than non-carriers.
RCT Entities:
OBJECTIVE: A minor allele variant (rs3798220) of apolipoprotein(a) has been reported to be associated with elevated plasma lipoprotein(a) [Lp(a)] and increased cardiovascular risk. We investigated whether this allele was associated with elevated Lp(a) and cardiovascular risk in the Women's Health Study, a randomized trial of low-dose aspirin, and whether aspirin reduced cardiovascular risk in minor allele carriers. METHODS AND RESULTS: Genotypes of rs3798220 were determined for 25,131 initially healthy Caucasian participants. Median Lp(a) levels at baseline were 10.0, 79.5, and 153.9mg/dL for major allele homozygotes, heterozygotes, and minor allele homozygotes, respectively (P<0.0001). During the 9.9 years of follow-up, minor allele carriers (3.7%) in the placebo group had twofold higher risk of major cardiovascular events than non-carriers (age-adjusted hazard ratio (HR)=2.21, 95% CI: 1.39-3.52). Among carriers, risk was reduced more than twofold by aspirin: for aspirin compared with placebo the age-adjusted HR was 0.44 (95% CI: 0.20-0.94); risk was not significantly reduced among non-carriers (age-adjusted HR=0.91, 95% CI: 0.77-1.08). This interaction between carrier status and aspirin allocation was significant (P=0.048). CONCLUSIONS: In the Women's Health Study, carriers of an apolipoprotein(a) variant had elevated Lp(a), doubled cardiovascular risk, and appeared to benefit more from aspirin than non-carriers.
Authors: E Anglés-Cano; L Hervio; D Rouy; C Fournier; J M Chapman; M Laplaud; M L Koschinsky Journal: Chem Phys Lipids Date: 1994-01 Impact factor: 3.329
Authors: Florian Kronenberg; Arno Lingenhel; Karl Lhotta; Barbara Rantner; Martina F Kronenberg; Paul König; Joachim Thiery; Michael Koch; Arnold von Eckardstein; Hans Dieplinger Journal: Kidney Int Date: 2004-07 Impact factor: 10.612
Authors: Mark A Hancock; Michael B Boffa; Santica M Marcovina; Michael E Nesheim; Marlys L Koschinsky Journal: J Biol Chem Date: 2003-04-15 Impact factor: 5.157
Authors: Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss Journal: J Lipid Res Date: 2010-08-16 Impact factor: 5.922
Authors: Euan A Ashley; Atul J Butte; Matthew T Wheeler; Rong Chen; Teri E Klein; Frederick E Dewey; Joel T Dudley; Kelly E Ormond; Aleksandra Pavlovic; Alexander A Morgan; Dmitry Pushkarev; Norma F Neff; Louanne Hudgins; Li Gong; Laura M Hodges; Dorit S Berlin; Caroline F Thorn; Katrin Sangkuhl; Joan M Hebert; Mark Woon; Hersh Sagreiya; Ryan Whaley; Joshua W Knowles; Michael F Chou; Joseph V Thakuria; Abraham M Rosenbaum; Alexander Wait Zaranek; George M Church; Henry T Greely; Stephen R Quake; Russ B Altman Journal: Lancet Date: 2010-05-01 Impact factor: 79.321
Authors: Rui-Sheng Wang; Damien C Croteau-Chonka; Edwin K Silverman; J Loscalzo; Scott T Weiss; Kathryn T Hall Journal: Clin Pharmacol Ther Date: 2019-10-28 Impact factor: 6.875
Authors: Dov Shiffman; Daniel I Chasman; Christie M Ballantyne; Vijay Nambi; James J Devlin; Eric Boerwinkle Journal: Thromb Haemost Date: 2009-07 Impact factor: 5.249